Skip to main content
Top
Published in: Radiation Oncology 1/2017

Open Access 01-12-2017 | Research

A dosimetric model for the heterogeneous delivery of radioactive nanoparticles In vivo: a feasibility study

Authors: Andrew B. Satterlee, Peter Attayek, Bentley Midkiff, Leaf Huang

Published in: Radiation Oncology | Issue 1/2017

Login to get access

Abstract

Accurate and quantitative dosimetry for internal radiation therapy can be especially challenging, given the heterogeneity of patient anatomy, tumor anatomy, and source deposition. Internal radiotherapy sources such as nanoparticles and monoclonal antibodies require high resolution imaging to accurately model the heterogeneous distribution of these sources in the tumor. The resolution of nuclear imaging modalities is not high enough to measure the heterogeneity of intratumoral nanoparticle deposition or intratumoral regions, and mathematical models do not represent the actual heterogeneous dose or dose response. To help answer questions at the interface of tumor dosimetry and tumor biology, we have modeled the actual 3-dimensional dose distribution of heterogeneously delivered radioactive nanoparticles in a tumor after systemic injection.

Methods

24 h after systemic injection of dually fluorescent and radioactive nanoparticles into a tumor-bearing mouse, the tumor was cut into 342 adjacent sections and imaged to quantify the source distribution in each section. The images were stacked to generate a 3D model of source distribution, and a novel MATLAB code was employed to calculate the dose to cells on a middle section in the tumor using a low step size dose kernel.

Results

The average dose calculated by this novel 3D model compared closely with standard ways of calculating average dose, and showed a positive correlation with experimentally determined cytotoxicity in vivo. The high resolution images allowed us to determine that the dose required to initiate radiation-induced H2AX phosphorylation was approximately one Gray. The nanoparticle distribution was further used to model the dose distribution of two other radionuclides.

Conclusions

The ability of this model to quantify the absorbed dose and dose response in different intratumoral regions allows one to investigate how source deposition in different tumor areas can affect dose and cytotoxicity, as well as how characteristics of the tumor microenvironment, such as hypoxia or high stromal areas, may affect the potency of a given dose.
Appendix
Available only for authorised users
Literature
1.
go back to reference Buch K, Morancy T, Kaplan I, et al. Improved dosimetry in prostate brachytherapy using high resolution contrast enhanced magnetic resonance imaging: a feasibility study. J Contemp Brachytherapy. 2015;6(4):337–43.PubMed Buch K, Morancy T, Kaplan I, et al. Improved dosimetry in prostate brachytherapy using high resolution contrast enhanced magnetic resonance imaging: a feasibility study. J Contemp Brachytherapy. 2015;6(4):337–43.PubMed
2.
go back to reference Lee WR, deGuzman AF, Tomlinson SK, McCullough DL. Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy. Radiother Oncol. 2002;65(2):123–7.CrossRefPubMed Lee WR, deGuzman AF, Tomlinson SK, McCullough DL. Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy. Radiother Oncol. 2002;65(2):123–7.CrossRefPubMed
3.
go back to reference Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47(7):1209–11.PubMed Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47(7):1209–11.PubMed
4.
go back to reference Kennedy A. Selective internal radiation therapy dosimetry. Future Oncol. 2014;10(15 Suppl):77–81.CrossRefPubMed Kennedy A. Selective internal radiation therapy dosimetry. Future Oncol. 2014;10(15 Suppl):77–81.CrossRefPubMed
5.
go back to reference Lee YSK JS, Cho KD, Kang JH, Lim SM. Tumor dosimetry for I-131 trastuzumab therapy in a Her2+ NCI N87 xenograft mouse model using the Siemens SYMBIA E gamma camera with a pinhole collimator. J Instrum. 2015;10:P07001.CrossRef Lee YSK JS, Cho KD, Kang JH, Lim SM. Tumor dosimetry for I-131 trastuzumab therapy in a Her2+ NCI N87 xenograft mouse model using the Siemens SYMBIA E gamma camera with a pinhole collimator. J Instrum. 2015;10:P07001.CrossRef
6.
go back to reference Mjekiqi E. Estimation of the absorbed dose to patients treated with 177LuDotatate with regards to the long-term retention and radionuclide impurity in the form of 177mLu Medical Radiation Physics. www.lup.lub.lu.se/student-papers/record/3364795/file/3364801.pdf: Lund University, 2012:111. Mjekiqi E. Estimation of the absorbed dose to patients treated with 177LuDotatate with regards to the long-term retention and radionuclide impurity in the form of 177mLu Medical Radiation Physics. www.lup.lub.lu.se/student-papers/record/3364795/file/3364801.pdf: Lund University, 2012:111.
7.
go back to reference Schmitt A, Bernhardt P, Nilsson O, et al. Biodistribution and dosimetry of 177Lu-labeled [DOTA0, Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm. 2003;18(4):593–9.CrossRefPubMed Schmitt A, Bernhardt P, Nilsson O, et al. Biodistribution and dosimetry of 177Lu-labeled [DOTA0, Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm. 2003;18(4):593–9.CrossRefPubMed
8.
go back to reference Palm S, Back T, Haraldsson B, Jacobsson L, Lindegren S, Albertsson P. Biokinetic modeling and dosimetry for optimizing intraperitoneal radioimmunotherapy of ovarian cancer microtumors. J Nucl Med. 2016;57(4):594–600.CrossRefPubMed Palm S, Back T, Haraldsson B, Jacobsson L, Lindegren S, Albertsson P. Biokinetic modeling and dosimetry for optimizing intraperitoneal radioimmunotherapy of ovarian cancer microtumors. J Nucl Med. 2016;57(4):594–600.CrossRefPubMed
9.
go back to reference Zhu X, Palmer MR, Makrigiorgos GM, Kassis AI. Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis. Med Phys. 2010;37(6):2974–84.CrossRefPubMedPubMedCentral Zhu X, Palmer MR, Makrigiorgos GM, Kassis AI. Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis. Med Phys. 2010;37(6):2974–84.CrossRefPubMedPubMedCentral
10.
go back to reference Kwok CS, Prestwich WV, Wilson BC. Calculation of radiation doses for nonuniformity distributed beta and gamma radionuclides in soft tissue. Med Phys. 1985;12(4):405–12.CrossRefPubMed Kwok CS, Prestwich WV, Wilson BC. Calculation of radiation doses for nonuniformity distributed beta and gamma radionuclides in soft tissue. Med Phys. 1985;12(4):405–12.CrossRefPubMed
11.
go back to reference Vaziri B, Wu H, Dhawan AP, Du P, Howell RW. MIRD pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations. J Nucl Med. 2014;55(9):1557–64.CrossRefPubMed Vaziri B, Wu H, Dhawan AP, Du P, Howell RW. MIRD pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations. J Nucl Med. 2014;55(9):1557–64.CrossRefPubMed
12.
go back to reference Howard DM, Kearfott KJ, Wilderman SJ, Dewaraja YK. Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations. Cancer Biother Radiopharm. 2011;26(5):615–21.CrossRefPubMedPubMedCentral Howard DM, Kearfott KJ, Wilderman SJ, Dewaraja YK. Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations. Cancer Biother Radiopharm. 2011;26(5):615–21.CrossRefPubMedPubMedCentral
13.
go back to reference Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013;54(1):83–9.CrossRefPubMed Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013;54(1):83–9.CrossRefPubMed
14.
go back to reference van der Have F, Vastenhouw B, Ramakers RM, et al. U-SPECT-II: An Ultra-High-Resolution Device for Molecular Small-Animal Imaging. J Nucl Med. 2009;50(4):599–605.CrossRefPubMed van der Have F, Vastenhouw B, Ramakers RM, et al. U-SPECT-II: An Ultra-High-Resolution Device for Molecular Small-Animal Imaging. J Nucl Med. 2009;50(4):599–605.CrossRefPubMed
15.
go back to reference Park S, Yu AR, Choi YY, Kim HJ. Performance evaluation of a new CZT-based pre-clinical SPECT system. J Nucl Med. 2014;55:2138. Park S, Yu AR, Choi YY, Kim HJ. Performance evaluation of a new CZT-based pre-clinical SPECT system. J Nucl Med. 2014;55:2138.
18.
go back to reference Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858–68.CrossRefPubMed Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858–68.CrossRefPubMed
19.
go back to reference Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer. 2004;112(4):693–700.CrossRefPubMed Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer. 2004;112(4):693–700.CrossRefPubMed
20.
go back to reference Satterlee AB, Yuan H, Huang L. A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging. J Control Release. 2015;217:170–82.CrossRefPubMedPubMedCentral Satterlee AB, Yuan H, Huang L. A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging. J Control Release. 2015;217:170–82.CrossRefPubMedPubMedCentral
21.
go back to reference Satterlee AB, Huang L. Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform. Theranostics. 2016;6(7):918–29.CrossRefPubMedPubMedCentral Satterlee AB, Huang L. Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform. Theranostics. 2016;6(7):918–29.CrossRefPubMedPubMedCentral
22.
go back to reference Li J, Yang Y, Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release. 2012;158(1):108–14.CrossRefPubMed Li J, Yang Y, Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release. 2012;158(1):108–14.CrossRefPubMed
23.
go back to reference Satterlee AB, Rojas JD, Dayton PA, Huang L. Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy. Theranostics. 2017;7(2):253–69.CrossRefPubMedPubMedCentral Satterlee AB, Rojas JD, Dayton PA, Huang L. Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy. Theranostics. 2017;7(2):253–69.CrossRefPubMedPubMedCentral
24.
go back to reference Honig MG, Hume RI. Dil and diO: versatile fluorescent dyes for neuronal labelling and pathway tracing. Trends Neurosci. 1989;12(9):333–5. 40–1.CrossRefPubMed Honig MG, Hume RI. Dil and diO: versatile fluorescent dyes for neuronal labelling and pathway tracing. Trends Neurosci. 1989;12(9):333–5. 40–1.CrossRefPubMed
25.
go back to reference Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467–75.PubMed Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467–75.PubMed
26.
go back to reference Howell RW, Wessels BW, Loevinger R, et al. The MIRD perspective 1999. Medical Internal Radiation Dose Committee. J Nucl Med. 1999;40(1):3S–10S.PubMed Howell RW, Wessels BW, Loevinger R, et al. The MIRD perspective 1999. Medical Internal Radiation Dose Committee. J Nucl Med. 1999;40(1):3S–10S.PubMed
27.
go back to reference Cross WG, Freedman NO, Wong PY. Beta-ray dose distributions from point sources in an infinite water medium. Health Phys. 1992;63(2):160–71.CrossRefPubMed Cross WG, Freedman NO, Wong PY. Beta-ray dose distributions from point sources in an infinite water medium. Health Phys. 1992;63(2):160–71.CrossRefPubMed
28.
go back to reference Wendt R. Beta-ray dose kernels for Ho-166 and Lu-177. J Nucl Med. 2010;51(Supplement 2):1428. Wendt R. Beta-ray dose kernels for Ho-166 and Lu-177. J Nucl Med. 2010;51(Supplement 2):1428.
29.
go back to reference Walrand S, Hanin FX, Pauwels S, Jamar F. Tumour control probability derived from dose distribution in homogeneous and heterogeneous models: assuming similar pharmacokinetics, (125)Sn-(177)Lu is superior to (90)Y-(177)Lu in peptide receptor radiotherapy. Phys Med Biol. 2012;57(13):4263–75.CrossRefPubMed Walrand S, Hanin FX, Pauwels S, Jamar F. Tumour control probability derived from dose distribution in homogeneous and heterogeneous models: assuming similar pharmacokinetics, (125)Sn-(177)Lu is superior to (90)Y-(177)Lu in peptide receptor radiotherapy. Phys Med Biol. 2012;57(13):4263–75.CrossRefPubMed
30.
go back to reference Zhang J, Miao L, Guo S, et al. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J Control Release. 2014;182:90–6.CrossRefPubMed Zhang J, Miao L, Guo S, et al. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J Control Release. 2014;182:90–6.CrossRefPubMed
31.
go back to reference Graf F, Fahrer J, Maus S. DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy. PLoS One. 2014;9(2):e88239.CrossRefPubMedPubMedCentral Graf F, Fahrer J, Maus S. DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy. PLoS One. 2014;9(2):e88239.CrossRefPubMedPubMedCentral
32.
go back to reference MacPhail SH, Banath JP, Yu TY, Chu EH, Lambur H, Olive PL. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol. 2003;79(5):351–8.CrossRefPubMed MacPhail SH, Banath JP, Yu TY, Chu EH, Lambur H, Olive PL. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol. 2003;79(5):351–8.CrossRefPubMed
33.
go back to reference Lassmann M, Hanscheid H, Gassen D, et al. In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2010;51(8):1318–25.CrossRefPubMed Lassmann M, Hanscheid H, Gassen D, et al. In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2010;51(8):1318–25.CrossRefPubMed
34.
go back to reference Rothkamm K, Balroop S, Shekhdar J, Fernie P, Goh V. Leukocyte DNA damage after multi-detector row CT: a quantitative biomarker of low-level radiation exposure. Radiology. 2007;242(1):244–51.CrossRefPubMed Rothkamm K, Balroop S, Shekhdar J, Fernie P, Goh V. Leukocyte DNA damage after multi-detector row CT: a quantitative biomarker of low-level radiation exposure. Radiology. 2007;242(1):244–51.CrossRefPubMed
Metadata
Title
A dosimetric model for the heterogeneous delivery of radioactive nanoparticles In vivo: a feasibility study
Authors
Andrew B. Satterlee
Peter Attayek
Bentley Midkiff
Leaf Huang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2017
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-017-0794-z

Other articles of this Issue 1/2017

Radiation Oncology 1/2017 Go to the issue